Postpartum hemorrhage is a political failure—yet it can be prevented

Postpartum hemorrhage (PPH) remains one of the leading causes of maternal death globally, not because it is untreatable, but because societies and systems have failed to prioritize women's lives. This is not primarily a clinical failure; it is a political one. PPH is predictable. It is diagnosable. It is treatable. Yet in countries such as Kenya, maternal mortality ratios remain unacceptably high—around 355 deaths per 100 000 live births in Kenya, and closer to 400 in other parts of East and West Africa. These numbers are not abstractions. They represent women who died bringing life into the world, and families permanently altered by loss. If such mortality rates affected men, the global response would be immediate and uncompromising. A critical gap in the fight against PPH is political engagement. Policymakers usually respond to data, scale, and visibility, yet maternal deaths (particularly those occurring during childbirth) remain largely invisible within political decision making. Too often, those with the power to allocate resources, shape health systems, and remove barriers are absent from the conversations that could effect change. Where political leadership aligns with evidence-based care, the results are striking. In settings where heat-stable uterotonics such as heat-stable carbetocin have been introduced, particularly in areas where cold-chain storage for oxytocin is unreliable, maternal deaths from PPH have been dramatically reduced. These outcomes underscore a simple truth: appropriate technology when matched to context saves lives. Innovation does not need to be complex. One of the most persistent challenges in managing PPH is the delay in recognizing it is happening. Visual estimation of blood loss is unreliable. Introducing simple, reusable blood-collection drapes enables objective measurement, earlier diagnosis, and faster escalation of care will result in faster escalation. Timely action is critically important and often the difference between life and death. Equally important is combination therapy. The co-ordinated use of uterotonics, tranexamic acid (TXA), and misoprostol, delivered according to clear protocols, has proven effective in reducing mortality. When such interventions are embedded into national Essential Medicines Lists, availability improves, procurement increases, and lives are saved. Policy decisions directly translate into clinical outcomes. Training and task-sharing are also indispensable. Health workers at all levels, including those in primary and community settings, must be empowered to act decisively. Community-based providers, when properly trained and supported, can administer life-saving medications safely and appropriately. Controversy around certain drugs should not impede access when evidence clearly supports their use to prevent maternal death. PPH cannot be addressed in isolation. Anemia, hypertensive disorders, and poor nutritional status significantly increase the risk of severe bleeding and death during childbirth. Preventing PPH therefore requires a continuum-of-care approach—one that includes antenatal nutrition, micronutrient supplementation, and early identification and management of high-risk conditions such as preeclampsia. In Makueni County, we are proud to have achieved a significant milestone: zero maternal deaths from postpartum hemorrhage in public health facilities in both 2023 and 2024, through an approach that places women's lives firmly as a political priority. At its core, PPH exposes how much societies value women. In most households, women are the central pillar, sustaining families, economies, and communities. Allowing them to die from preventable causes during childbirth is indefensible. Ending preventable death from PPH demands more than guidelines; it requires political will, sustained investment, and accountability. Policymakers must be brought into the room, confronted with the evidence, and compelled to act. Maternal survival should not depend on geography, income, or luck. The question is not whether we know how to stop women dying from PPH—we do. The question is whether we are willing, collectively and politically, to decide that women's lives are worth saving. The author declares no conflicts of interest. ChatGPT was used to condense the original presentation transcript of the speaker into an initial editorial draft; all content, final edits and approvals were made by the authors. Data sharing is not applicable to this article as no new data were created or analyzed in this study.